1-[3-(4-bromophenyl)-2-oxopropyl]-3-(oxolan-2-ylmethyl)-7-(4-phenylbutanoyl)quinazoline-2,4-dione
C32H31BrN2O5 — CID 165011424
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[3-(4-bromophenyl)-2-oxopropyl]-3-(oxolan-2-ylmethyl)-7-(4-phenylbutanoyl)quinazoline-2,4-dione
1-[3-(4-bromophenyl)-2-oxopropyl]-3-(oxolan-2-ylmethyl)-7-(4-phenylbutanoyl)quinazoline-2,4-dione (PubChem CID 165011424) has the molecular formula C32H31BrN2O5 and a molecular weight of 603.51 g/mol. Its IUPAC name is 1-[3-(4-bromophenyl)-2-oxopropyl]-3-(oxolan-2-ylmethyl)-7-(4-phenylbutanoyl)quinazoline-2,4-dione.
Molecular Properties
| Compound Name | 1-[3-(4-bromophenyl)-2-oxopropyl]-3-(oxolan-2-ylmethyl)-7-(4-phenylbutanoyl)quinazoline-2,4-dione |
|---|---|
| PubChem CID | 165011424 |
| Molecular Formula | C32H31BrN2O5 |
| Molecular Weight | 603.51 g/mol |
| Exact Mass | 602.14 |
| IUPAC Name | 1-[3-(4-bromophenyl)-2-oxopropyl]-3-(oxolan-2-ylmethyl)-7-(4-phenylbutanoyl)quinazoline-2,4-dione |
| SMILES | O=C(Cc1ccc(Br)cc1)Cn1c(=O)n(CC2CCCO2)c(=O)c2ccc(C(=O)CCCc3ccccc3)cc21 |
| InChI | InChI=1S/C32H31BrN2O5/c33-25-14-11-23(12-15-25)18-26(36)20-34-29-19-24(30(37)10-4-8-22-6-2-1-3-7-22)13-16-28(29)31(38)35(32(34)39)21-27-9-5-17-40-27/h1-3,6-7,11-16,19,27H,4-5,8-10,17-18,20-21H2 |
| InChIKey | JTPLTRTZTIRWDH-UHFFFAOYSA-N |
| XLogP | 5.12 |
| TPSA | 87.37 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 11 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 603.51 |
| LogP ≤ 5 | 5.12 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 165011424 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.